Public-registry trials using Albipagrastim alf that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
| Trial | Sponsor | Condition | Phase | Sites |
| Phase II Study of QLC2519 in Pediatric Solid Tumor Participants | Qilu Pharmaceutical Co., Ltd. | Pediatric Malignant Solid Tumor | PHASE2 | 1 |
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →